FiltersReset Filters

With box warnings

Without box warnings

Branded

Generic

6 results

enhertu
(fam-trastuzumab deruxtecan-nxki)
Daiichi Sankyo Inc.
Usage: ENHERTU is indicated for treating adult patients with unresectable or metastatic HER2-positive breast cancer, HER2-low or HER2-ultralow breast cancer, HER2-mutant non-small cell lung cancer, advanced HER2-positive gastric cancer, and unresectable HER2-positive solid tumors, all following prior systemic therapies.
kadcyla
(ADO-TRASTUZUMAB EMTANSINE)
Genentech, Inc.
Usage: KADCYLA is indicated for treating HER2-positive metastatic breast cancer in patients who have previously received trastuzumab and a taxane, or for early breast cancer in those with residual disease after neoadjuvant therapy. Patient selection should use an FDA-approved companion diagnostic.
margenza
(margetuximab-cmkb)
MacroGenics, Inc
Usage: MARGENZA is indicated for treating adult patients with metastatic HER2-positive breast cancer, in combination with chemotherapy, who have previously received two or more anti-HER2 regimens, including one for metastatic disease.
perjeta
(Pertuzumab)
Genentech, Inc.
Usage: PERJETA is indicated for treating adults with HER2-positive metastatic breast cancer in combination with trastuzumab and docetaxel, as well as for neoadjuvant and adjuvant treatment of HER2-positive early breast cancer at high risk of recurrence, in combination with trastuzumab and chemotherapy.
phesgo
(pertuzumab, trastuzumab, and hyaluronidase-zzxf)
Genentech, Inc.
Usage: PHESGO is indicated for combination with chemotherapy in adults with HER2-positive early breast cancer for neoadjuvant and adjuvant treatment, and for those with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy. Patient selection is based on an FDA-approved diagnostic test.
tukysa
(tucatinib)
SEAGEN INC.
Usage: TUKYSA is indicated for adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including those with brain metastases, and for those with RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer that progressed after standard chemotherapy. It requires prior anti-HER2 therapy for approval.

Medications for Metastatic Human Epidermal Growth Factor 2 Positive Carcinoma Of Breast

enhertu

kadcyla

margenza

perjeta

phesgo

tukysa